Tharimmune Inc., a biotechnology company focusing on therapeutic candidates for inflammation and immunology, has announced key appointments to its executive leadership and board. Sireesh Appajosyula has been appointed as Chief Executive Officer, transitioning from his previous role as Chief Operating Officer. Vincent LoPriore has been named Executive Chairman of the Board, having served as a board member since April 2025. Additionally, James Gordon Liddy has joined the Board of Directors. These changes aim to advance the company's strategic initiatives and pipeline development.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。